Intermittent administration of parathyroid hormone (PTH 1–34), teriparatide, is anabolic for bone and is a well-established treatment for osteoporosis (Estell and Rosen, 2021). Both PTH and PTHrP act through the PTH1R to drive bone formation, increase bone mass, and lower fracture risk (Goltzman, 2018). It has been established that one mechanism for PTH-driven osteogenesis is through induction of cyclic AMP and the PKA pathway, although PKC can also be activated by ligand binding to the PTH1R (Wein and Kronenberg, 2018). Downstream targets from PTH1R activation include IGF-1, FGF-2, Rankl, Sclerostin, Wnt signaling, salt-inducible kinases, and the BMPs (Wein and Kronenberg, 2018; Nishimori et al., 2019; Yu et al., 2012). Pth1r is expressed in chondrocytes, and the entire osteoblast lineage from early osteogenic progenitors to osteoblasts during which it is upregulated (Goltzman, 2018). Osteocytes and lining cells also express Pth1r (Goltzman, 2018; Wein and Kronenberg, 2018). Recent studies have noted that the PTH1R is also expressed in mature adipocytes and their immediate precursors, marrow adipocyte-like progenitors, or MALPs (Zhong et al., 2020).

Intermittent PTH treatment increases bone formation both by enhancing the number of osteoblasts and their function, resulting in higher bone mass (Balani et al., 2017). Several reports have demonstrated that PTH-induced lineage allocation of skeletal stromal cells into osteoblasts is at the expense of adipogenesis (Fan et al., 2017). This is consistent with human studies which confirmed that PTH treatment reduces bone marrow adiposity principally through a shift in lineage allocation (Maridas et al., 2019). The transcriptional mechanisms whereby PTH drives a progenitor cell toward an osteoblast are multiple, complex, and redundant. Previous study reported that genetic deletion of the PTH1R in Prrx1⁺ cells resulted in low bone mass and a marked increase in bone marrow adiposity (Fan et al., 2017). A previous study for the mechanisms that drive adipogenesis that identified Zfp467 as a gene markedly upregulated in the absence of the PTH1R (Fan et al., 2017). Zinc finger proteins (ZFPs) are one of the largest classes of transcription factors in eukaryotic genomes and Zfp521 and Zfp423 have been identified as critical determinants of both adipogenesis and osteogenesis (Ganss and Jheon, 2004; Kiviranta et al., 2013). Zfp467 has been reported to enhance both Sost and Pparg expression in marrow stromal cells, and is highly expressed in both adipocyte and osteoblast progenitors (Quach et al., 2011). Furthermore, an earlier study identified Zfp467 as a transcriptional regulator of lineage allocation among mesenchymal progenitors cells in the marrow (You et al., 2012). In accordance with that report, global genetic deletion of Zfp467 resulted in high bone mass and a reduction in bone marrow adipose tissue (BMAT) and peripheral adipose depots (Le et al., 2021). Hence, the inverse relationship between PTH1R and Zfp467 suggested an additional pathway by which PTH could impact lineage allocation. To determine the molecular mechanism of this interaction, Zfp467^-/- osteoblast progenitors were used for studying and a potential transcriptional modulator of the PTH1R, regulated by ZFP467, was identified. This report details both in vitro and in vivo studies, and points to a novel pathway that impacts skeletal formation through the PTH1R.

Previous study showed that global deletion of Zfp467 increased trabecular bone volume and cortical bone thickness, compared to wild-type mice at the age of 16 weeks (Le et al., 2021). And histomorphometry results showed higher structural and dynamic formation parameters in Zfp467^-/- mice vs. Zfp467^+/+ (Le et al., 2021). To assess whether the effect on bone mass seen in the Zfp467 global knockout (KO) mice was cell-autonomous to mesenchymal cells, we generated mice with deletion of Zfp467 in the limb MSCs by crossing Zfp467^fl/fl mice with the Prrx1Cre mice or AdipoqCre mice (Figure 1—figure supplement 1).

Similar to the global Zfp467 null mice, Prrx1Cre Zfp467 mice have increased trabecular bone mass

Body mass and body size were not significantly different between Prrx1Cre; Zfp467^fl/fl and control littermates in both males and females (data not shown). Micro-computed tomography (μCT) analysis showed that Prrx1Cre; Zfp467^fl/fl mice had higher trabecular bone volume fraction (Tb.BV/TV), greater connectivity density (Conn.D), and higher trabecular number (Tb.N) with a significant decrease in structural model index (SMI) and trabecular separation (Tb.Sp) in both males and females (Figure 1), indicating an increase in trabecular bone mass. Cortical thickness was increased, although not significantly in males and marginally decreased in females at this age. In contrast, tibial adipose tissue volume fraction in the marrow was significantly decreased in males (Figure 1B), and showed a similar non-significant trend in females (Figure 1D). Although the time point of examination differed (12 weeks here instead of 16 weeks in the global KO; Le et al., 2021), these results show that, overall, Prrx1Cre; Zfp467^fl/fl mice showed a similar bone phenotype to the global Zfp467 KO mice. It is therefore conceivable that progenitor fate was indeed altered in the global Zfp467 KO mice, resulting in significant beneficial skeletal changes.

Figure 1 with 2 supplements see all

Download asset Open asset

To assess the cellular activities that contributed to increased bone mass in male Prrx1Cre;Zfp467^fl/fl mice, static and dynamic histomorphometry was performed. Consistent with µCT, histomorphometric analysis showed that although the changes in BV/TV were not significant, the overall trend was clearly toward an increase, and Tb.N (p=0.0271) and number of osteoblasts/total area (N.Ob/T.Ar, p=0.0105) were markedly increased in Prrx1Cre;Zfp467^fl/fl male mice compared to Zfp467^fl/fl control (Table 1), confirming an increase in osteogenesis and bone mass. However, in contrast to global Zfp467 KO mice, the increased trabecular bone was observed in male Prrx1Cre;Zfp467^fl/fl mice only, whereas no significant changes in the bone phenotype were found in female mice between groups.

Table 1

	Male			Female
	Zfp467fl/fl	Prrx1Cre; Zfp467fl/fl	p-Value	Zfp467fl/fl	Prrx1Cre; Zfp467fl/fl	p-Value
BV/TV (%)	9.1482±2.6523	12.570±2.9694	0.06	7.4561±1.9473	8.1315±3.8504	0.71
Tb.Th (μm)	35.961±3.7772	37.700±5.8760	0.63	35.384±2.5611	34.748±6.5862	0.76
Tb.Sp (μm)	396.80±168.61	274.83±62.817	0.13	484.18±119.44	501.35±288.61	0.90
Tb.N (n/μm)	2.5294±0.6037	3.3260±0.4942	0.03	2.0813±0.4175	2.3440±1.1650	0.61
OS/BS (%)	21.767±11.722	31.987±12.704	0.16	14.244±5.1159	8.8012±4.2810	0.07
O.Th (μm)	2.0084±0.4411	4.8227±3.4306	0.07	3.1650±0.4587	3.4638±1.2793	0.60
Ob.S/BS (%)	16.672±7.6973	25.817±8.5871	0.07	21.776±6.8886	18.210±8.0428	0.43
N.Ob/B.Pm (n/mm)	12.333±5.4003	19.082±5.6469	0.05	17.250±5.1870	14.051±4.7140	0.29
Oc.S/BS (%)	10.601±3.6508	12.975±4.2334	0.31	18.439±4.7740	19.192±6.7888	0.83
N.Oc/B.Pm (n/mm)	5.3885±1.9701	6.3505±2.1171	0.42	8.7722±2.1935	9.6039±3.4546	0.63
MS/BS (%)	45.655±3.5366	43.990±4.3419	0.47	45.333±5.4009	44.027±1.8733	0.68
MAR (μm/day)	1.2265±0.2238	1.1889±0.1266	0.71	1.8148±0.1294	1.6824±0.4816	0.63
BFR/BS (μm3/μm3/day)	0.5634±0.1373	0.5220±0.0648	0.49	0.8207±0.0933	0.7457±0.2292	0.59
BFR/BV (%/day)	3.2079±1.2339	2.6756±0.5373	0.32	4.6232±0.4123	4.5078±1.7235	0.85

1. Data are means ± SD (n=6–7). BV/TV, bone volume/total volume; Tb.Th, trabecular thickness; Tb.Sp, trabecular separation; Tb.N, trabecular number; OS/BS, osteoid surface/bone surface; O.Th, osteoid thickness; Ob.S/BS, osteoblast surface/bone surface; N.Ob/B.Pm, osteoblast number/bone perimeter; Oc.S/BS, osteoclast surface/bone surface; N.Oc/BS, osteoclast number/ bone surface; N.Oc/B.Pm, osteoclast number/bone perimeter; MS/BS, mineralizing surface/ bone surface; MAR, mineral apposition ratio; BFR/BS, bone formation ratio/ one surface; BFR/BV, bone formation rate/bone surface.

PTH suppressed the expression levels of Zfp467 via the PKA pathway

To understand the mechanisms that underly the impact of mesenchymal deletion of Zfp467, the signaling pathway of PTH relative to Zfp467 in osteoblasts was examined by qPCR. Consistent with a previous study which showed that short-term PTH treatment suppressed the expression of Zfp467 (Quach et al., 2011), treating cells with 100 nM PTH for 10 min could significantly suppress Zfp467 expression in both COBs (Figure 2A) and bone marrow stromal cells (BMSCs) (Figure 2B). When pretreating COBs and BMSCs with PKA and PKC inhibitors (10 µM H89 and 5 µM Go6983, Selleck Chemicals, Houston, TX), respectively, for 2 hr prior to 10 min of 100 nM PTH treatment, significant rescue of Zfp467 suppression was seen in H89 group, but Go6983 had no effect (Figure 2C and D). Forskolin, a selective PKA pathway activator, was also found to significantly inhibit the expression level of Zfp467 in COBs (Figure 2E) and BMSCs (Figure 2F). Moreover, consistent with previous study that Prrx1Cre; Pth1r^fl/fl mice showed higher expression level of Zfp467 in bone marrow, silenced Pth1r with siRNA in both COBs and BMSC, and found Pth1r knockdown significantly upregulated the expression level of Zfp467 (Figure 2G and H). These data suggested that PTH1R activation could downregulate Zfp467 expression via the PKA pathway, and that ZFP467 could be one of the important downstream targets of PTH signaling.

Figure 2

Download asset Open asset

Zfp467^-/- cells have greater Pth1r transcriptional levels driven by both the P1 and P2 promoter

Our previous study showed that the global absence of Zfp467 resulted in a significant increase in trabecular bone volume, a marked reduction in peripheral and marrow adipose tissue, and an ~40% increase in Pth1r gene expression in bone from the Zfp467^-/- mice compared to littermate controls (Le et al., 2021). These data suggested the possibility of a positive feedback loop whereby the suppression of Zfp467 mediated by PTH leads to an increase of PTH1R. Consistent with this tenet, higher gene and protein expression level of PTH1R was found in Zfp467^-/- COBs and BMSCs (Figure 3A and B). Three transcripts of Pth1r (NM_011199.2, NM_001083935.1, and NM_001083936.1) with different transcription starting sites (TSS) were reported based on NCBI database and UCSC Genome Browser on Mouse (Figure 3C). The three transcripts shared the same coding sequence and the only difference was located at the 5’ untranslated region. Based on the different 5’ untranslated regions, related primers were designed; by qPCR both the Pth1r-T1 and Pth1r-T2 transcripts were upregulated in Zfp467^-/- cells (Figure 3D). However, the expression level of Pth1r-T2 was much higher than Pth1r-T1. Pth1r-T1 and Pth1r-T2 transcripts were driven by P1 and P2 promoters, respectively. As P1 is much longer than P2 and hadn’t been investigated before, a P1 promoter-driven dual-fluorescence reporter with four different length P1 promoters were designed to assess any change in the promoter activity of P1 in both COBs and BMSCs in the absence of 467 (Figure 3C). The 1.6 and 2.1 kb promoter-driven reporters are higher in activated Zfp46 ^-/- cells compared to Zfp467^+/+ cells (Figure 3E), which indicated the binding site of Pth1r P1 promoter in Zfp467 ^-/- cells is between 0.6 and 1.1 kb ahead of P1 TSS.

Figure 3

Download asset Open asset

Figure 3—source data 1

Western blot for Figure 3B.

https://cdn.elifesciences.org/articles/83345/elife-83345-fig3-data1-v2.zip

Download elife-83345-fig3-data1-v2.zip

Figure 3—source data 2

Western blot for Figure 3B PTH1R in calvarial osteoblasts (COBs).

https://cdn.elifesciences.org/articles/83345/elife-83345-fig3-data2-v2.zip

Download elife-83345-fig3-data2-v2.zip

Figure 3—source data 3

Western blot for Figure 3B ACTIN in calvarial osteoblasts (COBs).

https://cdn.elifesciences.org/articles/83345/elife-83345-fig3-data3-v2.zip

Download elife-83345-fig3-data3-v2.zip

Figure 3—source data 4

Western blot for Figure 3B PTH1R in bone marrow stromal cells (BMSCs).

https://cdn.elifesciences.org/articles/83345/elife-83345-fig3-data4-v2.zip

Download elife-83345-fig3-data4-v2.zip

Figure 3—source data 5

Western blot for Figure 3B ACTIN in bone marrow stromal cells (BMSCs).

https://cdn.elifesciences.org/articles/83345/elife-83345-fig3-data5-v2.zip

Download elife-83345-fig3-data5-v2.zip

Combined with the previously reported two potential transcription factor binding sites of P2 (Tohmonda et al., 2013), three P1- and P2-driven dual-fluorescence reporters were constructed (Figure 3F). Both P1 and P2 were activated in Zfp467^-/- cells, but P2 showed much higher activity in BMSCs and COBs. P2-2 was also much more active in Zfp467^-/- cells than Zfp467^+/+ cells. P2-2 was therefore chosen for transcription factor prediction via JASPAR, Animal TFDB and PROMO databases; six transcription factors predicted by all three databases were noted, including CREB, EBF1, MYOD, cFOS, NFκB1, and GATA1.

Zfp467^-/- cells have higher NFκB1 and GATA1 nuclear translocation

Using qPCR, no differences in the transcriptional levels of these transcription factors was observed (Figure 4—figure supplement 1). Therefore, those potential transcription factors that could bind to cryptic sites in the Pth1r P2-2 promoter in a pre-osteoblast cell line MC3T3-E1 were overexpressed subsequently. Only GATA1 and NFκB1 overexpression could significantly upregulate the expression level of Pth1r, especially Pth1r-T1 and -T2 (Figure 4A). Nuclear translocation level of NFκB1 and GATA1 were further detected using immunofluorescence, nuclear protein isolation, and western blot. NFκB1 and GATA1 were almost evenly distributed in the cytoplasm and nucleus of Zfp467^+/+ cells but underwent partial translocation to the nucleus in Zfp467^-/- cells (Figure 4B). Zfp467^-/- cells also showed much higher nuclear protein level of both NFκB1 and GATA1 (Figure 4C and D).

Figure 4 with 1 supplement see all

Download asset Open asset

Figure 4—source data 1

Western blot for Figure 3C.

https://cdn.elifesciences.org/articles/83345/elife-83345-fig4-data1-v2.zip

Download elife-83345-fig4-data1-v2.zip

Figure 4—source data 2

Western blot for Figure 3C ACTIN.

https://cdn.elifesciences.org/articles/83345/elife-83345-fig4-data2-v2.zip

Download elife-83345-fig4-data2-v2.zip

Figure 4—source data 3

Western blot for Figure 3C H3.

https://cdn.elifesciences.org/articles/83345/elife-83345-fig4-data3-v2.zip

Download elife-83345-fig4-data3-v2.zip

Figure 4—source data 4

Western blot for Figure 3C p50 in cytoplasm.

https://cdn.elifesciences.org/articles/83345/elife-83345-fig4-data4-v2.zip

Download elife-83345-fig4-data4-v2.zip

Figure 4—source data 5

Western blot for Figure 3C GATA1 in cytoplasm.

https://cdn.elifesciences.org/articles/83345/elife-83345-fig4-data5-v2.zip

Download elife-83345-fig4-data5-v2.zip

Figure 4—source data 6

Western blot for Figure 3C GATA1 in nuclear.

https://cdn.elifesciences.org/articles/83345/elife-83345-fig4-data6-v2.zip

Download elife-83345-fig4-data6-v2.zip

Figure 4—source data 7

Western blot for Figure 3C p50 in nuclear.

https://cdn.elifesciences.org/articles/83345/elife-83345-fig4-data7-v2.zip

Download elife-83345-fig4-data7-v2.zip

An NFκB1-RelB heterodimer may drive greater Pth1r transcription in Zfp467^-/- cells

In order to confirm whether NFκB1 or GATA1 could activate the specific P1 or P2-2 Pth1r promoter, P1 and P2-2 dual-luciferase reporter and Gata1, Nfkb1 overexpression plasmids were co-transfected in MC3T3-E1 cells. Only the Nkfb1 overexpression group was able to significantly activate the P2-2 promoter (Figure 5A). Chromatin immunoprecipitation (ChIP) results showed that the DNA was properly sheared and IP was successfully conducted (Figure 5B). ChIP-qPCR results showed that the first two parts of P2 were properly enriched in our IP product (>0.5%) (Figure 5—figure supplement 1A), and the first part of P2 was approximately 20-fold more highly enriched in our NFκB1 IP product than IgG (Figure 5C, Figure 5—figure supplement 1B); this indicated that NFκB1 binds to the P2 promoter, especially at the first 200 bp site. Subsequently, COBs and BMSCs were treated with Nfkb1 siRNA and showed that Nfkb1 knockdown could significantly inhibit the expression of Pth1r in both Zfp467^+/+ and Zfp467^-/- COBs and BMSCs. Importantly, Nfkb1 knockdown in Zfp467^-/- cells reverts the levels of Pth1r to the levels seen in Zfp467^+/+ cells (Figure 5D–G).

Figure 5 with 1 supplement see all

Download asset Open asset

Figure 5—source data 1

Western blot for Figure 5B and F.

https://cdn.elifesciences.org/articles/83345/elife-83345-fig5-data1-v2.zip

Download elife-83345-fig5-data1-v2.zip

Figure 5—source data 2

Western blot for Figure 5B p50 with IP samples.

https://cdn.elifesciences.org/articles/83345/elife-83345-fig5-data2-v2.zip

Download elife-83345-fig5-data2-v2.zip

Figure 5—source data 3

Western blot for Figure 5C PTH1R.

https://cdn.elifesciences.org/articles/83345/elife-83345-fig5-data3-v2.zip

Download elife-83345-fig5-data3-v2.zip

Figure 5—source data 4

Western blot for Figure 5C p50.

https://cdn.elifesciences.org/articles/83345/elife-83345-fig5-data4-v2.zip

Download elife-83345-fig5-data4-v2.zip

Figure 5—source data 5

Western blot for Figure 5C ACTIN.

https://cdn.elifesciences.org/articles/83345/elife-83345-fig5-data5-v2.zip

Download elife-83345-fig5-data5-v2.zip

In order to determine whether NFκB1 could bind to the Pth1r P2-2 promoter directly, DNA pulldown assay was performed using biotin-labeled Pth1r P2 promoter as a probe. As shown in Figure 6A, the biotin-Pth1rP2 group showed a specific band in both MC3T3-E1 nuclear extracts and purified NFκB1 protein, suggesting a direct physical interaction between NFκB1 and Pth1r P2 promoter. However, noticed that NFκB1 does not have a transcriptional activation domain, NFκB1 must heterodimerize with other transcription factors in order to increase gene transcription. Using String database and checking published studies, eight candidates that might heterodimerize with NFκB1 to regulate gene transcription were obtained: NFYC, NPAS1, Rel, AKAP8, RelA, RelB, ANKRD42, and HDAC1. Using siRNA to knock down all these potential NFκB1 partners (Figure 6B), the upregulated Pth1r induced by Nfkb1 overexpression could only be dampened by Npas1 and Relb siRNA (Figure 6C). Further co-immunoprecipitation (co-IP) results confirmed that NFκB1 could heterodimerize with RelB only (Figure 6D), which suggested that NFκB1-Relb heterodimers may drive greater Pth1r transcription in Zfp467^-/- cells.

Figure 6 with 1 supplement see all

Download asset Open asset

Figure 6—source data 1

Western blot for Figure 6A, D, E, F and G.

https://cdn.elifesciences.org/articles/83345/elife-83345-fig6-data1-v2.zip

Download elife-83345-fig6-data1-v2.zip

Figure 6—source data 2

Western blot for Figure 6A p50 in DNA pulldown experiment using nuclear extract.

https://cdn.elifesciences.org/articles/83345/elife-83345-fig6-data2-v2.zip

Download elife-83345-fig6-data2-v2.zip

Figure 6—source data 3

Western blot for Figure 6A p50 in DNA pulldown experiment using p50 purified protein.

https://cdn.elifesciences.org/articles/83345/elife-83345-fig6-data3-v2.zip

Download elife-83345-fig6-data3-v2.zip

Figure 6—source data 4

Western blot for Figure 6D RelB.

https://cdn.elifesciences.org/articles/83345/elife-83345-fig6-data4-v2.zip

Download elife-83345-fig6-data4-v2.zip

Figure 6—source data 5

Western blot for Figure 6D NPAS1.

https://cdn.elifesciences.org/articles/83345/elife-83345-fig6-data5-v2.zip

Download elife-83345-fig6-data5-v2.zip

Figure 6—source data 6

Western blot for Figure 6D p50.

https://cdn.elifesciences.org/articles/83345/elife-83345-fig6-data6-v2.zip

Download elife-83345-fig6-data6-v2.zip

Figure 6—source data 7

Western blot for Figure 6E p-p105.

https://cdn.elifesciences.org/articles/83345/elife-83345-fig6-data7-v2.zip

Download elife-83345-fig6-data7-v2.zip

Figure 6—source data 8

Western blot for Figure 6E p50/p105.

https://cdn.elifesciences.org/articles/83345/elife-83345-fig6-data8-v2.zip

Download elife-83345-fig6-data8-v2.zip

Figure 6—source data 9

Western blot for Figure 6E ACTIN.

https://cdn.elifesciences.org/articles/83345/elife-83345-fig6-data9-v2.zip

Download elife-83345-fig6-data9-v2.zip

Figure 6—source data 10

Western blot for Figure 6F NFκB-inducing kinase (NIK).

https://cdn.elifesciences.org/articles/83345/elife-83345-fig6-data10-v2.zip

Download elife-83345-fig6-data10-v2.zip

Figure 6—source data 11

Western blot for Figure 6F ACTIN.

https://cdn.elifesciences.org/articles/83345/elife-83345-fig6-data11-v2.zip

Download elife-83345-fig6-data11-v2.zip

Figure 6—source data 12

Western blot for Figure 6F p-IKKα/β.

https://cdn.elifesciences.org/articles/83345/elife-83345-fig6-data12-v2.zip

Download elife-83345-fig6-data12-v2.zip

Figure 6—source data 13

Western blot for Figure 6F IKKα.

https://cdn.elifesciences.org/articles/83345/elife-83345-fig6-data13-v2.zip

Download elife-83345-fig6-data13-v2.zip

Figure 6—source data 14

Western blot for Figure 6G p-p100.

https://cdn.elifesciences.org/articles/83345/elife-83345-fig6-data14-v2.zip

Download elife-83345-fig6-data14-v2.zip

Figure 6—source data 15

Western blot for Figure 6G p100.

https://cdn.elifesciences.org/articles/83345/elife-83345-fig6-data15-v2.zip

Download elife-83345-fig6-data15-v2.zip

Given that post-translational regulation is essential for NF-κB activity, whether more proximal events in the NF-κB signaling cascade are impacted in Zfp467-deficient cells were also determined. p50, p105, and p105 phosphorylation was measured in Zfp467 siRNA-treated MC3T3-E1 cells; no significant difference between groups was observed (Figure 6E). Therefore, ZFP467 may have no effect on p105 proteasomal processing and p50 production.

In the non-canonical NFκB pathway, NFκB-inducing kinase (NIK) is constitutively degraded by the proteasome and this process is TRAF3 and TRAF2-dependent. And when non-canonical NFκB signaling is activated, TRAF2 and TRAF3 are recruited to the receptors, TRAF3 will be degraded and NIK stabilization is achieved. Accumulated NIK then phosphorylates IKKα and helps IKKα to phosphorylate p100. Phosphorylated p100 will be degraded followed by ubiquitination and relieve RelB, then RelB can heterodimerize with p50 and be transported to the nucleus. Furthermore, higher protein levels of NIK was found in Zfp467 knockdown cells, but there was no difference in its transcriptional level (Figure 6F). Moreover, in Zfp467 knockdown cells, higher phosphorylation level of both IKKα and p100 was observed (Figure 6G), which suggested the non-canonical NFκB pathway was activated. Although slightly higher transcriptional level of Ikka was found, there were no differences in its protein level.

In order to investigate whether there was a stimulus between Zfp467 and non-canonical NFκB pathway, the expression level of a few classic non-canonical NFκB pathway stimuli and related receptors in Zfp467 siRNA-treated MC3T3-E1 cells were detected; we found Rankl, Ltb, and Baff was much higher in Zfp467 siRNA-treated MC3T3-E1 cells than control cells (Figure 6—figure supplement 1).

Zfp467^-/- cells have increased PTH signaling and higher extracellular acidification rates

As the PKA pathway is considered to be one of the major downstream pathways of the PTH signaling network, it would be important to know whether Zfp467 ^-/- cells have higher PKA activation levels due to the higher expression of PTH1R. PTH increased cAMP within 10 min,measured by ELISA in Zfp467^+/+ COBs, and Zfp467^-/- cells had a higher levels of cAMP expression than Zfp467^+/+ cells (p=0.0007 for vehicle, p<0.0001 for 50 nM, p=0.0008 for 100 nM). In addition, Zfp467^-/- BMSCs also had significantly higher levels of intracellular cAMP after 10–60 min exposure of PTH (p<0.0001 for 10 min-100 nM, p=0.0341 for 30 min-100 nM, p<0.0001 for 60 min-100 nM) (Figure 7A and B). Importantly, Zfp467^-/- COBs and BMSCs showed a greater magnitude of increase of cAMP after PTH treatment (p=0.0053 for interaction in COBs, p=0.0010 for interaction in BMSCs), which resulted from higher PTH1R in Zfp467^-/- cells. Additionally, as CREB was one of the major downstream targets of PKA, higher p-CREB in Zfp467^-/-COBs and BMSCs was observed whereas the total protein level of CREB showed no difference (Figure 7C and D).

Figure 7

Download asset Open asset

Figure 7—source data 1

Western blot for Figure 7C.

https://cdn.elifesciences.org/articles/83345/elife-83345-fig7-data1-v2.zip

Download elife-83345-fig7-data1-v2.zip

Figure 7—source data 2

Western blot for Figure 7C p-CREB in calvarial osteoblasts (COBs).

https://cdn.elifesciences.org/articles/83345/elife-83345-fig7-data2-v2.zip

Download elife-83345-fig7-data2-v2.zip

Figure 7—source data 3

Western blot for Figure 7C CREB in calvarial osteoblasts (COBs).

https://cdn.elifesciences.org/articles/83345/elife-83345-fig7-data3-v2.zip

Download elife-83345-fig7-data3-v2.zip

Figure 7—source data 4

Western blot for Figure 7C ACTIN in calvarial osteoblasts (COBs).

https://cdn.elifesciences.org/articles/83345/elife-83345-fig7-data4-v2.zip

Download elife-83345-fig7-data4-v2.zip

Figure 7—source data 5

Western blot for Figure 7C p-CREB in bone marrow stromal cells (BMSCs).

https://cdn.elifesciences.org/articles/83345/elife-83345-fig7-data5-v2.zip

Download elife-83345-fig7-data5-v2.zip

Figure 7—source data 6

Western blot for Figure 7C CREB in bone marrow stromal cells (BMSCs).

https://cdn.elifesciences.org/articles/83345/elife-83345-fig7-data6-v2.zip

Download elife-83345-fig7-data6-v2.zip

Figure 7—source data 7

Western blot for Figure 7C ACTIN in bone marrow stromal cells (BMSCs).

https://cdn.elifesciences.org/articles/83345/elife-83345-fig7-data7-v2.zip

Download elife-83345-fig7-data7-v2.zip

In a previous study, PTH was shown to enhance aerobic glycolysis, which is a major source of ATP for osteoblast differentiation (Esen et al., 2015). The oxygen consumption and extracellular acidification in both COBs and BMSCs was measured pre-osteogenic differentiation and 3 days after osteogenic differentiation. Cellular respiration measurements showed that Zfp467^-/- pre-differentiated COBs had significantly increased extracellular acidification rates (ECAR), but no difference was found for pre-differentiated BMSCs in respect to either ECAR or oxygen consumption rate (OCR) (Figure 7E and F). However, both Zfp467^-/- COBs and BMSCs cells had significantly higher ECAR levels after 3 days of osteogenic differentiation, although no difference was found regarding OCR between genotypes (Figure 7G and H). These data suggest that Zfp467^-/- COBs or BMSCs may have higher glycolysis as a result of higher PTH1R expression.

Zfp467^-/- cells showed increased sensitivity to PTH and enhanced pro-osteogenic as well as anti-adipogenic effects

To determine the sensitivity of Zfp467^-/- cells to PTH, COBs were treated with osteogenic differentiation media and PTH for 7 or 14 days simultaneously. A dose response to PTH led to a significant increase in alkaline phosphatase (ALP) staining in Zfp467^-/- COBs, and in Zfp467^+/+ cells. Furthermore, 100 nM PTH in Zfp467^-/- cells produced remarkably higher positive-stained cells than vehicle group (p=0.0001) while there was no statistical significance seen among Zfp467^+/+ groups (p=0.6536) (Figure 8A and B). Importantly, Zfp467^-/- COBs showed a more significant response to PTH regarding ALP and alizarin red staining (p=0.0201 for ALP, p=0.0210 for ARS) (Figure 8B). ARS showed a parallel trend as ALP staining; an increase in PTH dose resulted in an increase in mineralization for Zfp467 ^-/- COBs only (Figure 8A).

Figure 8

Download asset Open asset

In osteogenic media, lipid stored in osteoblasts was observed. Significantly less lipid droplets in Zfp467^-/- osteoblasts were noted compared to untreated Zfp467^+/+ samples (Figure 8C). Additionally, a reduction in lipid droplet formation was observed with PTH exposure at 50 and 100 nM in both Zfp467^+/+ and Zfp467^-/- cells, and Zfp467^-/- cells showed much less lipid droplet formation compared to +/+ group (Figure 8C and D). However, the magnitude of decrease after PTH treatment is almost identical in Zfp467^+/+ and Zfp467^-/- cells (Figure 8D). These results were then confirmed by qRT-PCR after 7 days’ osteogenic differentiation which indicated higher expression of osteogenic differentiation-related genes such as Alp, Sp7, Rankl, and Igf1 in Zfp467^-/- compared to Zfp467^+/+ COBs with PTH exposure (Figure 8E and F). It is noteworthy that there is a statistically significant interaction between genotype and PTH treatment, suggesting an increased sensitivity to PTH in Zfp467^-/- cells.

In order to prove that absence of Zfp467 increases the expression of the PTH1R and influences PTH-induced osteoblastogenesis in vivo, Zfp467 global KO mice was treated with PTH for 1 week and compared those responses to control mice. Although no much difference was observed between vehicle and the 1-week PTH-treated group in Zfp467^+/+ mice, PTH-treated Zfp467^-/- mice had higher BT/TV (p=0.0572), Conn.D (p=0.0755) and lower Tb.Sp (p=0.0811) and SMI (p=0.0399) than PTH-treated Zfp467^+/+ mice, even after only 1 week of treatment.

Gene silencing of Pth1r or PKA inhibitors suppressed Zfp467^-/- induced increased osteogenic differentiation

To determine whether the increase in osteogenic differentiation seen in Zfp467^-/- cells is due to higher PTH1r levels, Pth1r was knocked down by siRNA and found that Pth1r knockdown led to decreased osteogenic differentiation in both Zfp467^+/+ and Zfp467^-/- COBs. Although Zfp467^-/- COBs still show slightly higher Alp staining (Figure 9A), Pth1r knockdown in Zfp467^-/- cells dampens the increase in Alp and Sp7 gene expression during osteogenic differentiation compared to Zfp467^+/+ cells, indicating that this increase is associated with the upregulation of Pth1r seen in Zfp467^-/- cells (Figure 9B).

Figure 9 with 1 supplement see all

Download asset Open asset

Furthermore, a PKA inhibitor could also significantly decrease osteogenic differentiation in COBs (Figure 9C). The staining showed ALP activity was much higher in Zfp467^-/- cells in the absence of the PKA inhibitor, but no difference was found with the PKA inhibitor between genotypes (Figure 9C). In addition, with the PKA inhibitor, upregulated osteogenic genes in Zfp467 ^-/- cells including Alp and Sp7 could be totally reversed (Figure 9C). Similarly, treating COBs with the PKA inhibitor during PTH treatment simultaneously for 7 days led to a suppression of osteogenic differentiation in both Zfp467^+/+ and Zfp467^-/- cells (Figure 9—figure supplement 1). qPCR results showed that PKA inhibitor could totally reverse the upregulation of Alp, Sp7, and Rankl in PTH-treated Zfp467^-/- cells (Figure 9—figure supplement 1A,B).

Wdfy1, Sox10, and Ngfr are downstream targets of ZFP467

Next question would be what were the downstream targets of Zfp467. In an unbiased analysis, using RNA-seq in pre- and post-differentiated COBs from Zfp467^+/+ and Zfp467^-/- cells, potential regulatory pathways and differentially expressed genes (DEG) were obtained (Figure 10A–D). The PI 3K and MAPK signaling pathways were differentially upregulated in Zfp467^-/- cells whether pre- or post-differentiated when compared to Zfp467^+/+ cells (Figure 10D). There were several highly expressed genes in the Zfp467^-/- cells related to osteogenesis, including Wdfy1, Sox10, and Ngfr (Figure 10B). These results were confirmed by qRT-PCR (Figure 10E). When Zfp467 was overexpressed in MC3T3-E1 cells those three genes were significantly suppressed relative to GFP overexpression.

Figure 10

Download asset Open asset

Based on above data, the role of Zfp467 was identified in the molecular, cellular, and biochemical responses to PTH in osteoblast progenitors and in vivo. A novel pathway was reported by which PTH can enhance its own anabolic actions in osteoblast progenitors by repressing Zfp467, a negative regulator of PTH1R expression. Zfp467 was originally isolated from mouse hematogenic endothelial LO cells as an OSM-inducible mRNA, which encodes protein ZFP467 (Nakayama et al., 2002), also called EZI. Zinc finger motifs are involved in protein-protein interactions and protein-DNA binding (Ganss and Jheon, 2004; Leon and Roth, 2000; Berg, 1990). Based on the zinc finger domain, ZFPs are classified into C2H2, C3H, and C4 (Varnum et al., 1991). ZFP467 belongs to C2H2 ZFP family whose zinc finger domain consists of two cysteine and two histidine residues. ZFP467 was initially found to cooperate with STAT3 and augment STAT3 activity by enhancing its nuclear translocation in a kidney cell line (Nakayama et al., 2002). ZFP467 is expressed ubiquitously and may be an important mediator of BMSC differentiation into the adipogenic or osteogenic lineages as well as functioning in other tissues in distinct ways (Quach et al., 2011; You et al., 2012; You et al., 2015).

Deletion of Pth1r in mesenchymal cells resulted in low bone mass, high marrow adiposity, and upregulation of Zfp467 (Fan et al., 2017). In contrast, the absence of Zfp467 resulted in a significant increase in Tb.BV/TV, accompanied by a marked reduction in peripheral and marrow adipose tissue and improved glucose tolerance (Le et al., 2021). Most importantly for the current study, whole bone marrow gene expression by qRT-PCR revealed an ~40% increase in Pth1r expression and greater protein levels in the Zfp467^-/- mice compared to controls (Le et al., 2021). Therefore, PTH1R and ZFP467 could be involved in a feedback loop whereby the suppression of Zfp467 mediated by PTH leads to an increase of PTH1R, and therefore an enhanced response to PTH treatment. However, due to the global nature of the Zfp467 deletion, a cell non-autonomous effect could not be excluded. In the present study therefore, we tested that hypothesis both in vivo and in vitro, and sought to determine the cellular and biochemical mechanisms involved in this novel regulatory pathway.

First, we were able to show that conditional deletion of Zfp467 by Prrx1Cre led to an increase in osteogenesis and bone formation, a finding that mirrors our results with the global deletion of Zfp467, although, it should be noted that the increased trabecular bone in Prrx1Cre;Zfp467^fl/fl was much more pronounced in male rather than female mice. On the other hand, using an AdipoqCre-driven system, no effect of conditional deletion in adipocytes on body composition, fat mass, bone mass, or total weight was observed. Taken together these data would suggest that Zfp467 is an early mesenchymal transcriptional factor that regulates lineage allocation in early osteoblast but not adipocyte progenitors. Second, constitutive upregulation of Zfp467 was observed when we genetically knocked down Pth1r in COBs and BMSCs. In addition, much like the study of Quach et al., 2011, acute PTH treatment could significantly suppress gene expression of Zfp467 in both COBs and BMSCs, and the suppression could be partly rescued by both a PKA pathway inhibitor and a PKC inhibitor (Quach et al., 2011). Similarly, Forskolin, a PKA pathway activator, could also inhibit the expression of Zfp467, with a more sustained effect. These data indicated that PTH might suppress Zfp467 expression via activation of the PTH1R through predominantly PKA pathways.

To test the validity of the hypothesis, how deletion of Zfp467 affected the expression of the PTH1R was further investigated. The transcript of Pth1r that upregulated in Zfp467 absent cells was further confirmed that via dual-fluorescence reporter assay that both P1 and P2 promoters of Pth1r were activated in Zfp467 null cells; however, P2 was more activated than P1. Using three different transcription factor prediction databases including PROMO, JASPAR, and Animal TFDB, several candidate transcription factors that might be involved in the regulation of Pth1r in Zfp467^-/- cells via activation of the P2 promoter were observed. After overexpressing each candidate transcription factor, only NFκB1 could upregulate Pth1r via activation of the P2-2 Pth1r promoter. Further confocal immunofluorescence and nuclear protein detection indicated that the nuclear translocation of NFκB1 was much higher in Zfp467^-/- cells. Moreover, ChIP-qPCR results showed that NFκB1 could bind to the P2 promoter of the Pth1r. Taken together, these data suggested that the deletion of Zfp467 resulted in higher nuclear translocation of NFκB1 which bound to the P2 promoter of Pth1r and promoted its transcription.

NFκB1 is one of the DNA binding subunits of the NF-kappa-B (NFκB) protein complex. NFκB is a transcriptional regulator that is activated by various stimuli including cytokines, bacteria, and oxidation. The NFκB pathway is involved in several biological processes including inflammation, bone resorption, aging, and cancer (Cartwright and Perkins, 2016). Activated NFκB1 translocates into the nucleus and stimulates the expression of an array of genes. However, no previous studies that NFκB1 may regulate the gene expression of Pth1r or other osteogenic-related genes. Nevertheless, it was reported that time- and stage-specific inhibition of endogenous inhibitors of IκB kinase (IKK)–nuclear factor-κB (NF-κB) in differentiated osteoblasts substantially increases trabecular bone mass and bone mineral density without affecting osteoclast activities (Chang et al., 2009). Therefore, activation of NF-κB may not only regulate osteoclast activation and bone resorption but also simultaneously be involved in osteoblast function, thus influencing bone formation and maintaining bone homeostasis. It is also conceivable that NFκB1 could associate with histone deacetylase-1 (HDAC1) or be regulated by a PKA catalytic subunit which is also downstream of PTH signaling in osteoblasts (Yu et al., 2009). Moreover, it is likely that other proteins like RelB that might bind to p50 and enhance its effect on the transcriptional regulation of Pth1r play a critical role in PTH-mediated osteogenesis. In addition to RelB-p50 heterodimers, more proximal events in the non-canonical NFκB signaling cascade was detected and higher phosphorylation level of both IKKα and p100 were observed in Zfp467 knock down cells, which suggested the non-canonical NFκB pathway was activated when lacking Zfp467, and was involved in the transcriptional regulation of Pth1r.

Osteoblasts require substrates for energy utilization during collagen synthesis and mineralization. Previous reports by Lee et al. and Guntur et al. demonstrated that glycolysis is a major source of ATP for differentiating osteoblasts (Maridas et al., 2019; Esen et al., 2015). Consistently, Zfp467^-/-cells showed higher cAMP levels in response to PTH as well as higher glycolytic activity (i.e. ECAR). COBs from Zfp467^-/- mice also showed greater differentiation in osteogenic media but less differentiation into adipocytes compared to controls. Higher rates of osteogenesis, enhanced Rankl and Igf1 expression, increased glycolysis, and decreased adipogenesis are likely related to greater activation of the PTH1R, possibly due to its higher endogenous expression level. Consistently, after treating Zfp467 global KO mice with PTH for 1 week and compared to control mice, PTH-treated Zfp467^-/- mice showed higher bone volume and lower SMI than PTH-treated Zfp467^+/+ mice.

Since it was reported that the downstream effects of PTH could be partially blocked by PKA inhibitors (Ishizuya et al., 1997), Pth1r siRNA and PKA inhibitors were used to block the effect of PTH1R, which confirmed that PTH1R and its downstream pathways were involved in the deletion of Zfp467-induced osteogenic differentiation. ALP staining and qPCR results suggested that Pth1r siRNA and PKA inhibitor could nearly reverse the upregulated osteogenic differentiation in Zfp467^-/- COBs with or without PTH treatment.

Last but not least, RNA-seq was performed to identify potential downstream targets and pathways of Zfp467 that might be involved in the regulation of osteogenic differentiation. Among the top three upregulated genes in Zfp467^-/- COBs, Wdfy1 plays an important role in the innate immune responses by mediating TLR3/4 signaling (Hu et al., 2015; Yang et al., 2020), which might be also involved in the regulation of osteoblast metabolism and function (Alonso-Pérez et al., 2018; Vega-Letter et al., 2016). Another significantly upregulated gene, Ngfr in Zfp467^-/- cells was found to be required for skeletal cell migration and osteogenesis, especially during injury repair (Xu et al., 2022; Tomlinson et al., 2017). NGFR could also mediate AMP-induced modulation of ERK1/2 and AKT cascades (Piiper et al., 2002), which is consistent with our GSEA pathways enrichment. However, further investigation is required to clarify how ZFP467 regulates Wdfy1, Ngfr, and their downstream AKT or MAPK pathways.

Despite uncovering a novel regulatory circuit through NFκB1, there are some limitations to our study. First, it should be noted that Zfp467^-/- cells have higher nuclear translocation of GATA1 and overexpression of GATA1 could promote Pth1r expression. However, overexpression of GATA1 failed to activate the P2-2 promoter of Pth1r. Hence, that GATA1 might be another of the regulating transcription factors between ZFP467 and Pth1r, but it likely regulates Pth1r expression via binding sites other than those present on P2-2.

Second, how Zfp467 binds with NFκB1-RelB heterodimers was not determined, and we have not identified the exact genomic sequence required for NFκB1-RelB heterodimer binding at the P2 promoter binding site. Further studies will be needed to address this important mechanistic question. Hence the precise mechanism of action of Zfp467 and the downstream consequences of NFκB1-RelB heterodimer binding on the presumed switch between adipocytes and osteoblasts is still not fully defined. Last, to our knowledge, there must be a break on the activation of a feed-forward PTH-PTH1R regulatory system, but it is not delineated whereby the fast forward system interacts with β-arrestin or any other mechanism that turns off signaling.

In summary, taken together, we demonstrated the importance of the zinc finger protein ZFP467 for lineage allocation in vitro and in vivo, as well as responsiveness to PTH in osteoblast progenitors. Our data also support a novel feed-forward regulatory loop whereby suppression of Zfp467 mediated by PTH and its downstream PKA pathway leads to an increase of PTH1R via NFκB1, and subsequent enhanced responsiveness to PTH treatment (Figure 11). In addition, our lines of evidence suggest that the NF-κB signaling pathway may be an important component of the osteoblastic response to cytokines, and possibly to factors elaborated by osteoclasts, enhancing coupling of resorption to formation. These findings have significant implications for our understanding of the anabolic effects of PTH on bone.

Figure 11

Download asset Open asset

RNA-seq data that support the findings in this study are openly available in Sequence Read Archive database (PRJNA877934, http://www.ncbi.nlm.nih.gov/bioproject/877934).All data generated or analysed during this study are included in the manuscript and supporting file; Source Data files have been provided for Figures 3-Figure 7.

1. 1. Rosen C

   (2022) NCBI BioProject

   ID PRJNA877934. PTH regulates osteogenesis and suppresses adipogenesis through Zfp 467 in a feed-forward cyclic AMP dependent manner.

   https://www.ncbi.nlm.nih.gov/bioproject/PRJNA877934

1. 1. Alonso-Pérez A
   2. Franco-Trepat E
   3. Guillán-Fresco M
   4. Jorge-Mora A
   5. López V
   6. Pino J
   7. Gualillo O
   8. Gómez R

   (2018) Role of Toll-like receptor 4 on osteoblast metabolism and function

   Frontiers in Physiology 9:504.

   https://doi.org/10.3389/fphys.2018.00504

   • PubMed
   • Google Scholar
2. 1. Balani DH
   2. Ono N
   3. Kronenberg HM

   (2017) Parathyroid hormone regulates fates of murine osteoblast precursors in vivo

   The Journal of Clinical Investigation 127:3327–3338.

   https://doi.org/10.1172/JCI91699

   • PubMed
   • Google Scholar
3. 1. Berg JM

   (1990)

   Zinc fingers and other metal-binding domains. Elements for interactions between macromolecules

   The Journal of Biological Chemistry 265:6513–6516.

   • Google Scholar
4. 1. Cartwright T
   2. Perkins ND

   (2016) Nfkb1: a suppressor of inflammation, ageing and cancer

   The FEBS Journal 283:1812–1822.

   https://doi.org/10.1111/febs.13627

   • PubMed
   • Google Scholar
5. 1. Chang J
   2. Wang Z
   3. Tang E
   4. Fan Z
   5. McCauley L
   6. Franceschi R
   7. Guan K
   8. Krebsbach PH
   9. Wang CY

   (2009) Inhibition of osteoblastic bone formation by nuclear factor-κB

   Nature Medicine 15:682–689.

   https://doi.org/10.1038/nm.1954

   • Google Scholar
6. 1. Esen E
   2. Lee SY
   3. Wice BM
   4. Long F

   (2015) Pth promotes bone anabolism by stimulating aerobic glycolysis via IGF signaling

   Journal of Bone and Mineral Research 30:2137.

   https://doi.org/10.1002/jbmr.2714

   • PubMed
   • Google Scholar
7. 1. Estell EG
   2. Rosen CJ

   (2021) Emerging insights into the comparative effectiveness of anabolic therapies for osteoporosis

   Nature Reviews. Endocrinology 17:31–46.

   https://doi.org/10.1038/s41574-020-00426-5

   • PubMed
   • Google Scholar
8. 1. Fan Y
   2. Hanai JI
   3. Le PT
   4. Bi R
   5. Maridas D
   6. DeMambro V
   7. Figueroa CA
   8. Kir S
   9. Zhou X
   10. Mannstadt M
   11. Baron R
   12. Bronson RT
   13. Horowitz MC
   14. Wu JY
   15. Bilezikian JP
   16. Dempster DW
   17. Rosen CJ
   18. Lanske B

   (2017) Parathyroid hormone directs bone marrow mesenchymal cell fate

   Cell Metabolism 25:661–672.

   https://doi.org/10.1016/j.cmet.2017.01.001

   • PubMed
   • Google Scholar
9. 1. Ganss B
   2. Jheon A

   (2004) Zinc finger transcription factors in skeletal development

   Critical Reviews in Oral Biology and Medicine 15:282–297.

   https://doi.org/10.1177/154411130401500504

   • PubMed
   • Google Scholar
10. 1. Goltzman D

    (2018) Physiology of parathyroid hormone

    Endocrinology and Metabolism Clinics of North America 47:743–758.

    https://doi.org/10.1016/j.ecl.2018.07.003

    • PubMed
    • Google Scholar
11. 1. Hu YH
    2. Zhang Y
    3. Jiang LQ
    4. Wang S
    5. Lei CQ
    6. Sun MS
    7. Shu HB
    8. Liu Y

    (2015) WDFY1 mediates TLR3/4 signaling by recruiting TRIF

    EMBO Reports 16:447–455.

    https://doi.org/10.15252/embr.201439637

    • PubMed
    • Google Scholar
12. 1. Ishizuya T
    2. Yokose S
    3. Hori M
    4. Noda T
    5. Suda T
    6. Yoshiki S
    7. Yamaguchi A

    (1997) Parathyroid hormone exerts disparate effects on osteoblast differentiation depending on exposure time in rat osteoblastic cells

    Journal of Clinical Investigation 99:2961–2970.

    https://doi.org/10.1172/JCI119491

    • Google Scholar
13. 1. Jutras BL
    2. Verma A
    3. Stevenson B

    (2012) Identification of novel DNA‐binding proteins using DNA‐affinity chromatography/pull down

    Current Protocols in Microbiology 24:mc01f01s24.

    https://doi.org/10.1002/9780471729259.mc01f01s24

    • Google Scholar
14. 1. Kawai M
    2. Breggia AC
    3. DeMambro VE
    4. Shen X
    5. Canalis E
    6. Bouxsein ML
    7. Beamer WG
    8. Clemmons DR
    9. Rosen CJ

    (2011) The heparin-binding domain of IGFBP-2 has insulin-like growth factor binding-independent biologic activity in the growing skeleton

    The Journal of Biological Chemistry 286:14670–14680.

    https://doi.org/10.1074/jbc.M110.193334

    • PubMed
    • Google Scholar
15. 1. Kiviranta R
    2. Yamana K
    3. Saito H
    4. Ho DK
    5. Laine J
    6. Tarkkonen K
    7. Nieminen-Pihala V
    8. Hesse E
    9. Correa D
    10. Määttä J
    11. Tessarollo L
    12. Rosen ED
    13. Horne WC
    14. Jenkins NA
    15. Copeland NG
    16. Warming S
    17. Baron R

    (2013) Coordinated transcriptional regulation of bone homeostasis by Ebf1 and zfp521 in both mesenchymal and hematopoietic lineages

    The Journal of Experimental Medicine 210:969–985.

    https://doi.org/10.1084/jem.20121187

    • PubMed
    • Google Scholar
16. 1. Le PT
    2. Liu H
    3. Alabdulaaly L
    4. Vegting Y
    5. Calle IL
    6. Gori F
    7. Lanske B
    8. Baron R
    9. Rosen CJ

    (2021) The role of zfp467 in mediating the pro-osteogenic and anti-adipogenic effects on bone and bone marrow niche

    Bone 144:115832.

    https://doi.org/10.1016/j.bone.2020.115832

    • PubMed
    • Google Scholar
17. 1. Leon O
    2. Roth M

    (2000) Zinc fingers: DNA binding and protein-protein interactions

    Biological Research 33:21–30.

    https://doi.org/10.4067/S0716-97602000000100009

    • Google Scholar
18. 1. Maridas DE
    2. Rendina-Ruedy E
    3. Le PT
    4. Rosen CJ

    (2018) Isolation, culture, and differentiation of bone marrow stromal cells and osteoclast progenitors from mice

    Journal of Visualized Experiments 5:56750.

    https://doi.org/10.3791/56750

    • PubMed
    • Google Scholar
19. 1. Maridas DE
    2. Rendina-Ruedy E
    3. Helderman RC
    4. DeMambro VE
    5. Brooks D
    6. Guntur AR
    7. Lanske B
    8. Bouxsein ML
    9. Rosen CJ

    (2019) Progenitor recruitment and adipogenic lipolysis contribute to the anabolic actions of parathyroid hormone on the skeleton

    FASEB Journal 33:2885–2898.

    https://doi.org/10.1096/fj.201800948RR

    • PubMed
    • Google Scholar
20. 1. Nakayama K
    2. Kim K-W
    3. Miyajima A

    (2002) A novel nuclear zinc finger protein EZI enhances nuclear retention and transactivation of STAT3

    The EMBO Journal 21:6174–6184.

    https://doi.org/10.1093/emboj/cdf596

    • PubMed
    • Google Scholar
21. 1. Nishimori S
    2. O’Meara MJ
    3. Castro CD
    4. Noda H
    5. Cetinbas M
    6. da Silva Martins J
    7. Ayturk U
    8. Brooks DJ
    9. Bruce M
    10. Nagata M
    11. Ono W
    12. Janton CJ
    13. Bouxsein ML
    14. Foretz M
    15. Berdeaux R
    16. Sadreyev RI
    17. Gardella TJ
    18. Jüppner H
    19. Kronenberg HM
    20. Wein MN

    (2019) Salt-Inducible kinases dictate parathyroid hormone 1 receptor action in bone development and remodeling

    The Journal of Clinical Investigation 129:5187–5203.

    https://doi.org/10.1172/JCI130126

    • PubMed
    • Google Scholar
22. 1. Piiper A
    2. Dikic I
    3. Lutz MP
    4. Leser J
    5. Kronenberger B
    6. Elez R
    7. Cramer H
    8. Müller-Esterl W
    9. Zeuzem S

    (2002) Cyclic AMP induces transactivation of the receptors for epidermal growth factor and nerve growth factor, thereby modulating activation of MAP kinase, Akt, and neurite outgrowth in PC12 cells

    Journal of Biological Chemistry 277:43623–43630.

    https://doi.org/10.1074/jbc.M203926200

    • Google Scholar
23. 1. Quach JM
    2. Walker EC
    3. Allan E
    4. Solano M
    5. Yokoyama A
    6. Kato S
    7. Sims NA
    8. Gillespie MT
    9. Martin TJ

    (2011) Zinc finger protein 467 is a novel regulator of osteoblast and adipocyte commitment

    The Journal of Biological Chemistry 286:4186–4198.

    https://doi.org/10.1074/jbc.M110.178251

    • PubMed
    • Google Scholar
24. 1. Rosen CJ
    2. Dimai HP
    3. Vereault D
    4. Donahue LR
    5. Beamer WG
    6. Farley J
    7. Linkhart S
    8. Linkhart T
    9. Mohan S
    10. Baylink DJ

    (1997) Circulating and skeletal insulin-like growth factor-I (IGF-I) concentrations in two inbred strains of mice with different bone mineral densities

    Bone 21:217–223.

    https://doi.org/10.1016/s8756-3282(97)00143-9

    • PubMed
    • Google Scholar
25. 1. Scheller EL
    2. Troiano N
    3. Vanhoutan JN
    4. Bouxsein MA
    5. Fretz JA
    6. Xi Y
    7. Nelson T
    8. Katz G
    9. Berry R
    10. Church CD
    11. Doucette CR
    12. Rodeheffer MS
    13. Macdougald OA
    14. Rosen CJ
    15. Horowitz MC

    (2014) Use of osmium tetroxide staining with microcomputerized tomography to visualize and quantify bone marrow adipose tissue in vivo

    Methods in Enzymology 537:123–139.

    https://doi.org/10.1016/B978-0-12-411619-1.00007-0

    • PubMed
    • Google Scholar
26. 1. Tohmonda T
    2. Yoda M
    3. Mizuochi H
    4. Morioka H
    5. Matsumoto M
    6. Urano F
    7. Toyama Y
    8. Horiuchi K

    (2013) The IRE1α-XBP1 pathway positively regulates parathyroid hormone (PTH) /PTH-related peptide receptor expression and is involved in pth-induced osteoclastogenesis

    The Journal of Biological Chemistry 288:1691–1695.

    https://doi.org/10.1074/jbc.C112.424606

    • PubMed
    • Google Scholar
27. 1. Tomlinson RE
    2. Li Z
    3. Li Z
    4. Minichiello L
    5. Riddle RC
    6. Venkatesan A
    7. Clemens TL

    (2017) Ngf-Trka signaling in sensory nerves is required for skeletal adaptation to mechanical loads in mice

    PNAS 114:E3632–E3641.

    https://doi.org/10.1073/pnas.1701054114

    • Google Scholar
28. 1. Varnum BC
    2. Ma QF
    3. Chi TH
    4. Fletcher B
    5. Herschman HR

    (1991) The TIS11 primary response gene is a member of a gene family that encodes proteins with a highly conserved sequence containing an unusual Cys-His repeat

    Molecular and Cellular Biology 11:1754–1758.

    https://doi.org/10.1128/mcb.11.3.1754-1758.1991

    • PubMed
    • Google Scholar
29. 1. Vega-Letter AM
    2. Kurte M
    3. Fernández-O’Ryan C
    4. Gauthier-Abeliuk M
    5. Fuenzalida P
    6. Moya-Uribe I
    7. Altamirano C
    8. Figueroa F
    9. Irarrázabal C
    10. Carrión F

    (2016) Differential TLR activation of murine mesenchymal stem cells generates distinct immunomodulatory effects in EAE

    Stem Cell Research & Therapy 7:150.

    https://doi.org/10.1186/s13287-016-0402-4

    • PubMed
    • Google Scholar
30. 1. Wein MN
    2. Kronenberg HM

    (2018) Regulation of bone remodeling by parathyroid hormone

    Cold Spring Harbor Perspectives in Medicine 8:a031237.

    https://doi.org/10.1101/cshperspect.a031237

    • Google Scholar
31. Preprint

    1. Xu J
    2. Li Z
    3. Tower RJ
    4. Negri S
    5. Wang Y
    6. Meyers CA
    7. Sono T
    8. Qin Q
    9. Lu A
    10. Xing X
    11. McCarthy EF
    12. Clemens TL
    13. James AW

    (2022) NGF-P75 Signaling Coordinates Skeletal Cell Migration during Bone Repair

    bioRxiv.

    https://doi.org/10.1101/2021.07.07.451468

    • Google Scholar
32. 1. Yang Y
    2. Hu YH
    3. Liu Y

    (2020) Wdfy1 deficiency impairs TLR3-mediated immune responses in vivo

    Cellular & Molecular Immunology 17:1014–1016.

    https://doi.org/10.1038/s41423-020-0461-4

    • Google Scholar
33. 1. You L
    2. Pan L
    3. Chen L
    4. Chen JY
    5. Zhang X
    6. Lv Z
    7. Fu D

    (2012) Suppression of zinc finger protein 467 alleviates osteoporosis through promoting differentiation of adipose derived stem cells to osteoblasts

    Journal of Translational Medicine 10:11.

    https://doi.org/10.1186/1479-5876-10-11

    • PubMed
    • Google Scholar
34. 1. You L
    2. Chen L
    3. Pan L
    4. Gu WS
    5. Chen JY

    (2015) Zinc finger protein 467 regulates Wnt signaling by modulating the expression of sclerostin in adipose derived stem cells

    Biochemical and Biophysical Research Communications 456:598–604.

    https://doi.org/10.1016/j.bbrc.2014.11.120

    • PubMed
    • Google Scholar
35. 1. Yu Y
    2. Wan Y
    3. Huang C

    (2009) The biological functions of NF-kappaB1 (p50) and its potential as an anti-cancer target

    Current Cancer Drug Targets 9:566–571.

    https://doi.org/10.2174/156800909788486759

    • PubMed
    • Google Scholar
36. 1. Yu B
    2. Zhao X
    3. Yang C
    4. Crane J
    5. Xian L
    6. Lu W
    7. Wan M
    8. Cao X

    (2012) Parathyroid hormone induces differentiation of mesenchymal stromal/stem cells by enhancing bone morphogenetic protein signaling

    Journal of Bone and Mineral Research 27:2001–2014.

    https://doi.org/10.1002/jbmr.1663

    • PubMed
    • Google Scholar
37. 1. Zhong L
    2. Yao L
    3. Tower RJ
    4. Wei Y
    5. Miao Z
    6. Park J
    7. Shrestha R
    8. Wang L
    9. Yu W
    10. Holdreith N
    11. Huang X
    12. Zhang Y
    13. Tong W
    14. Gong Y
    15. Ahn J
    16. Susztak K
    17. Dyment N
    18. Li M
    19. Long F
    20. Chen C
    21. Seale P
    22. Qin L

    (2020) Single cell transcriptomics identifies a unique adipose lineage cell population that regulates bone marrow environment

    eLife 9:e54695.

    https://doi.org/10.7554/eLife.54695

    • PubMed
    • Google Scholar

Author details

1. Hanghang Liu

   1. Maine Medical Center Research Institute, Maine Medical Center, Scarborough, United States
   2. West China Hospital of Stomatology, Sichuan University, Sichuan, China

   Contribution

   Conceptualization, Data curation, Software, Formal analysis, Supervision, Funding acquisition, Investigation, Methodology, Writing - original draft, Project administration, Writing – review and editing

   Competing interests

   No competing interests declared

2. Akane Wada

   1. Division of Bone and Mineral Research, Dept of Oral Medicine, Infection and Immunity, Harvard School of Dental Medicine, Boston, United States
   2. Harvard Medical School, Department of Medicine and Endocrine Unit, Massachusetts General Hospital, Boston, United States

   Contribution

   Data curation, Software, Formal analysis, Investigation, Visualization, Methodology, Writing - original draft

   Competing interests

   No competing interests declared

3. Isabella Le

   1. Maine Medical Center Research Institute, Maine Medical Center, Scarborough, United States
   2. Graduate Medical Sciences, Boston University School of Medicine, Boston, United States

   Contribution

   Software, Formal analysis, Validation, Investigation, Visualization, Methodology

   Competing interests

   No competing interests declared

4. Phuong T Le

   Maine Medical Center Research Institute, Maine Medical Center, Scarborough, United States

   Contribution

   Data curation, Software, Formal analysis, Validation, Investigation, Methodology, Project administration, Writing – review and editing

   Competing interests

   No competing interests declared

5. Andrew WF Lee

   1. Maine Medical Center Research Institute, Maine Medical Center, Scarborough, United States
   2. University of New England, College of Osteopathic Medicine, Biddeford, United States

   Contribution

   Validation, Investigation

   Competing interests

   No competing interests declared

6. Jun Zhou

   1. Division of Bone and Mineral Research, Dept of Oral Medicine, Infection and Immunity, Harvard School of Dental Medicine, Boston, United States
   2. Harvard Medical School, Department of Medicine and Endocrine Unit, Massachusetts General Hospital, Boston, United States

   Contribution

   Data curation, Visualization, Methodology, Project administration, Writing – review and editing

   Competing interests

   No competing interests declared

7. Francesca Gori

   Division of Bone and Mineral Research, Dept of Oral Medicine, Infection and Immunity, Harvard School of Dental Medicine, Boston, United States

   Contribution

   Conceptualization, Supervision, Visualization, Methodology, Writing – review and editing

   Competing interests

   No competing interests declared

   "This ORCID iD identifies the author of this article:" 0000-0001-5685-8303

8. Roland Baron

   1. Division of Bone and Mineral Research, Dept of Oral Medicine, Infection and Immunity, Harvard School of Dental Medicine, Boston, United States
   2. Harvard Medical School, Department of Medicine and Endocrine Unit, Massachusetts General Hospital, Boston, United States

   Contribution

   Conceptualization, Supervision, Funding acquisition, Writing – review and editing

   Competing interests

   No competing interests declared

   Additional information

   Co-senior authors

9. Clifford J Rosen

   Maine Medical Center Research Institute, Maine Medical Center, Scarborough, United States

   Contribution

   Conceptualization, Supervision, Funding acquisition, Project administration, Writing – review and editing

   For correspondence

   cjrofen@gmail.com

   Competing interests

   No competing interests declared

   Additional information

   Co-senior authors

   "This ORCID iD identifies the author of this article:" 0000-0003-3436-8199

• 735

  views

• 146

  downloads

• 2

  citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.